(Q34181878)

31 July 2017

1 reference

title

A review of clinical experience with the prandial glucose regulator, repaglinide, in the treatment of type 2 diabetes (English)

1 reference

31 July 2017

1 reference

Moses R

1

1 reference

PubMed ID

11249478

31 July 2017

language of work or name

English

0 references

publication date

1 December 2000

1 reference

Expert Opinion on Pharmacotherapy

31 July 2017

1 reference

31 July 2017

1

1 reference

31 July 2017

7

1 reference

31 July 2017

1455-1467

1 reference

Insulin resistance as the major cause of impaired glucose tolerance: a self-fulfilling prophesy?

31 July 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.7.1455

A glimpse of the 'natural history' of established type 2 (non-insulin dependent) diabetes mellitus from the spectrum of metabolic and hormonal responses to a mixed meal at the time of diagnosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.7.1455

Metabolic abnormalities in impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.7.1455

Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.7.1455

Effect of a 3-day fast on glucose storage and oxidation in obese hyperinsulinemic diabetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.7.1455

Is there a concentration-effect relationship for sulphonylureas?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.7.1455

Problems and pitfalls of sulphonylurea therapy in older patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.7.1455

Higher incidence of severe hypoglycaemia leading to hospital admission in Type 2 diabetic patients treated with long-acting versus short-acting sulphonylureas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.7.1455

The emerging role of post-prandial hyperglycaemic spikes in the pathogenesis of diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.7.1455

Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.7.1455

Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.7.1455

Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.7.1455

Repaglinide versus glyburide: a one-year comparison trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.7.1455

A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.7.1455

Flexible prandial glucose regulation with repaglinide in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.7.1455

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.7.1455

Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.7.1455

Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.7.1455

10.1517/14656566.1.7.1455

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference

PubMed ID

11249478